Supplementary Table 3. Baseline characteristics of metformin users and non-users after propensity score matching in men

Variable	Men		p value
	Metformin users (n = 3,386)	Metformin non-users (n = 3,386)	
Age group (yr)			> 0.999
18–24	1 (0.0)	1 (0.0)	
25–34	21 (0.6)	21 (0.6)	
35–44	202 (6.0)	202 (6.0)	
45–54	629 (18.6)	629 (18.6)	
55–64	823 (24.3)	823 (24.3)	
65–74	823 (24.3)	823 (24.3)	
> 75	887 (26.2)	887 (26.2)	
Age (yr)	65 (54–75)	65 (54–75)	> 0.999
Region, metropolitan	1,416 (41.8)	1,518 (44.8)	0.01
Nationality, Korean	3,372 (99.6)	3,364 (99.4)	0.18
Household income			0.24
0 (lowest)	330 (9.8)	368 (10.9)	
1	548 (16.2)	494 (14.6)	
2	484 (14.3)	486 (14.4)	
3	513 (15.2)	541 (16.0)	
4	670 (19.8)	636 (18.8)	
5 (highest)	841 (24.8)	861 (25.4)	
Disability			< 0.01
No	2,783 (82.2)	2,752 (81.3)	
Physical disability	578 (17.1)	563 (16.6)	
Internal disability	25 (0.7)	71 (2.1)	
Lesion site of TB			
Pulmonary	3,110 (91.9)	3,019 (89.2)	< 0.01
Extra-pulmonary	276 (8.2)	367 (10.8)	< 0.01
TB history			
New case	2,874 (84.9)	2,846 (84.1)	0.35
Previously treated TB	512 (15.1)	540 (16.0)	0.35
PPM hospital	2,384 (70.4)	2,466 (72.8)	0.03
AFB smear positivity	1,371 (40.5)	1,360 (40.2)	0.12
Culture positivity	1,866 (55.1)	1,745 (51.5)	0.01
Charlson Comorbidity Index			> 0.999
0	1,121 (33.1)	1,121 (33.1)	
1	1,465 (43.3)	1,465 (43.3)	
2	250 (7.4)	250 (7.4)	
≥ 3	550 (16.2)	550 (16.2)	
Comorbidity			
Transplantation	7 (0.2)	46 (1.4)	< 0.01
HIV	1 (0.0)	2 (0.1)	0.56
Cancer	117 (3.5)	173 (5.1)	< 0.01

Supplementary Table 3. Continued

Variable	Men		p value
	Metformin users (n = 3,386)	Metformin non-users (n = 3,386)	
Notification year			> 0.999
2011	537 (15.9)	529 (15.6)	
2012	499 (14.7)	507 (15.0)	
2013	489 (14.4)	491 (14.5)	
2014	179 (14.2)	478 (14.1)	
2015	454 (13.4)	453 (13.4)	
2016	462 (13.6)	462 (13.6)	
2017	466 (13.8)	466 (13.8)	
Anti-diabetic treatment			
Sulfonylurea	1,950 (57.6)	2,111 (62.3)	< 0.01
Insulin	141 (4.2)	439 (13.0)	< 0.01
Other DM medication[a]	2,126 (62.8)	2,153 (63.6)	0.50
Follow-up duration (d)	224 (184–294)	237 (184–298)	0.23
Treatment outcome			< 0.01
Treatment success/failure	3,076 (90.8)	2,981 (88.0)	
Death due to all causes	310 (9.2)	405 (12.0)	
Cause of death			0.11
TB-related deaths	54 (1.6)	53 (1.6)	
Non-TB-related deaths	256 (7.6)	352 (10.4)	

Values are presented as number (%) or median (interquartile range).

AFB, acid-fast bacilli; DM, diabetes mellitus; HIV, human immunodeficiency virus; PPM, public-private mix; TB, tuberculosis.

[a]Other DM medications include dipeptidyl peptidase–4 inhibitors, glinide, thiazolidinedione, glucagon-like peptide-1, alpha-glucosidase inhibitors, and sodium-glucose cotransporter-2 inhibitors.